Overcoming challenges in the implementation of chimeric antigen receptor (CAR) T-cell therapy in resource-constrained settings: Lessons from Brazil and India.
Partnerships between academic centers and biotech companies are expanding CAR-T therapy access and reducing costs globally.
Advances in immunotherapy, including chimeric antigen receptor (CAR) T-cell therapy, have achieved remarkable outcomes in treating relapse/refractory hematologic malignancies. These efforts, supported by partnerships with academic institutions, international collaborations, and biotechnology companies, focus on expanding access and developing a cost-effective product.
What the study was
- Study design
- Literature review
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cytotherapy
Why it surfaced
Matched topic(s): Hematologic malignancies, Novel therapeutics: immunotherapy, CAR-T, targeted therapy. Study design: Literature review. Score 4/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.